Ultragenyx Pharmaceutical (RARE) Net Income (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Net Income of -$185.0 million for Q1 2026, down 22.52% year-over-year from -$238.8 million in Q1 2025, and down 50.95% quarter-over-quarter from -$122.6 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Net Income (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Net Income for 14 consecutive years, with -$185.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income fell 22.52% year-over-year to -$185.0 million; the TTM figure through Mar 2026 stood at -$602.9 million (down 10.56% YoY), while the FY2025 annual figure was -$569.0 million, down 0.71% from the prior year.
- Net Income fell to -$185.0 million in Q1 2026 per RARE's latest filing, from -$122.6 million in the prior quarter.
- Across five years, Net Income topped out at -$115.0 million in Q2 2025 and bottomed at -$245.1 million in Q3 2022.
- Historically, Net Income has averaged -$155.0 million across 5 years, with a median of -$153.5 million in 2022.
- Annual changes were most pronounced in 2022 — Net Income slumped 235.77% — and 2023, when it jumped 34.87%.
- Ultragenyx Pharmaceutical's Net Income stood at -$153.5 million in 2022, then advanced by 19.5% to -$123.6 million in 2023, then decreased by 4.57% to -$129.2 million in 2024, then rose by 5.14% to -$122.6 million in 2025, then slumped by 50.95% to -$185.0 million in 2026.
- Business Quant data shows RARE's Net Income at -$185.0 million in Q1 2026, -$122.6 million in Q4 2025, and -$180.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | -92.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -92.00 Mn |
| Mar 31, 2026 | -185.00 Mn |
| Dec 31, 2025 | -122.56 Mn |
| Sep 30, 2025 | -180.41 Mn |
| Jun 30, 2025 | -114.95 Mn |
| Mar 31, 2025 | -151.00 Mn |
| Dec 31, 2024 | -129.20 Mn |
| Sep 30, 2024 | -133.52 Mn |
| Jun 30, 2024 | -131.60 Mn |
| Mar 31, 2024 | -170.68 Mn |
| Dec 31, 2023 | -123.55 Mn |
| Sep 30, 2023 | -159.65 Mn |
| Jun 30, 2023 | -159.83 Mn |
| Mar 31, 2023 | -163.97 Mn |
| Dec 31, 2022 | -153.47 Mn |
| Sep 30, 2022 | -245.11 Mn |
| Jun 30, 2022 | -158.16 Mn |
| Mar 31, 2022 | -152.32 Mn |
| Dec 31, 2021 | 332.86 Mn |
| Sep 30, 2021 | -73.00 Mn |